Fingerprinting the circulating repertoire of antibodies from cancer patients
Article Abstract:
The phage-display random-peptide libraries are used to screen peptides binding to the repertoire of antibodies purified from whole serum that is derived from prostate cancer patients. This fingerprinting procedure is used to uncover and validate a specific prognostic serological marker as well as its corresponding native antigen and this method is useful in identifying molecular targets for therapy against cancer.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Tunable antibodies
Article Abstract:
Monoclonal antibodies (mAbs) are widely used for targeting cancer cells. A study highlights the progress in generating effective anti-cancer antibodies by manipulating antibody binding affinity and their ability to support antibody dependent cellular cytotoxicity (ADCC).
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
The rollercoaster ride to anti-cancer antibodies
Article Abstract:
Anticancer antibody development and effectiveness are discussed.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Evidence on the incremental information content of additional firm disclosures made concurrently with earnings
- Abstracts: Flying in the face of convention. Success in a nutshell. The unfriendly skies
- Abstracts: Management theory in translation. The business of design. GM's current woes reveal the price of corporate arrogance and amnesia
- Abstracts: Factors affecting the valuation of corporate bonds. Modern portfolio theory, 1950 to date. Optimal investment strategies with investor liabilities
- Abstracts: IAS 39 raises accounting row. Accounting giants recover poise after regulatory onslaught. Sony's new board game